Scientists Invented a Chewing Gum That Might Help Fight Cancer Some Day

Reported by Women's Health Magazine.

Head and neck cancers have been climbing in the U.S., and while human papillomavirus (HPV) gets most of the blame, other oral microbes are quietly making things worse. Now researchers at the University of Pennsylvania have engineered something unexpected to fight back: a chewing gum designed to neutralize cancer-causing bacteria and viruses before they colonize your mouth and throat.

According to Women's Health Magazine, the gum—made from bioengineered lablab bean proteins—showed stunning lab results. When tested on saliva samples from patients with head and neck squamous cell carcinoma (HNSCC), the gum reduced HPV levels by 93 percent. A specially formulated version containing an antimicrobial peptide called protegrin nearly eliminated two other dangerous microbes, Porphyromonas gingivalis and Fusobacterium nucleatum, which are linked to worse survival rates in oral cancers. The best part: it left beneficial oral bacteria untouched.

Why chewing gum? Because location matters.

Swallowed pills get diluted in your bloodstream and can't concentrate where the infection actually lives—your mouth. A medicated gum stays put, delivering antiviral and antibacterial proteins directly to the tissue where they're needed. The lablab bean proteins work by trapping viruses (a protein called FRIL literally sticks them to the gum) and punching holes in carcinogenic bacteria. Henry Daniell, the study's lead author and vice-chair of basic and translational sciences at UPenn's dental school, claims the gum neutralizes more than 95 percent of target viruses and pathogens.

But before you imagine swapping your regular gum for this, there's a reality check. Paolo Serafini, an immunologist at the University of Miami's Sylvester Comprehensive Cancer Center, raises a crucial question: how long does the effect actually last? His educated guess—around an hour—suggests the gum alone won't be a game-changer. He also notes that the HPV vaccine already prevents most cases of HNSCC without any chewing involved. Daniell emphasizes this would complement existing treatments, not replace them. Clinical trials are underway in London, with U.S. studies at UPenn coming soon, but we're still years away from knowing whether this innovation actually moves the needle in cancer prevention.

A promising lab finding doesn't automatically translate to real-world impact—but the specificity of local drug delivery is worth watching.

Read the original at Women's Health Magazine.